We are live on ! Find out more
MIRA icon

MIRA Pharmaceuticals

30 hedge funds and large institutions have $1.89M invested in MIRA Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

42,582% more capital inflows, than outflows

Capital inflows: $575K | Capital outflows: $1.35K

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

800% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 1

43% more funds holding

Funds holding: 21 → 30 (+9)

1.41% more ownership

Funds ownership: 5.91% → 7.32% (+1.4%)

Holders
30
Holders Change
+9
Holders Change %
+42.86%
% of All Funds
0.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
9
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

MIRA Hedge Fund Activity: Q3 2025 in Review

30 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in MIRA Pharmaceuticals (MIRA) for Q3 2025, worth a combined $1.89M — up 56% from $1.21M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new MIRA positions and 1 closed out — a net gain of 9 holders — while 9 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $159K. The largest seller was Fortitude Family Office, exiting entirely with an estimated $935 sold.

  • 30 institutional investors held MIRA Pharmaceuticals (MIRA) as of Q3 2025, up from 21 in Q2 2025.
  • Funds reported $1.89M of MIRA Pharmaceuticals stock for Q3 2025, up 56% quarter-over-quarter.
  • 10 funds opened new MIRA Pharmaceuticals positions in Q3 2025 and 1 closed out, a net change of +9 holders.
  • The largest MIRA Pharmaceuticals buyer in Q3 2025 was BlackRock, an estimated $159K added.
  • The largest MIRA Pharmaceuticals seller in Q3 2025 was Fortitude Family Office, an estimated $935 sold.

Based on aggregated 13F filings for Q3 2025.